TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: Other targeted agents tested in PTCL include BCL2 inhibitors (e.g., venetoclax [NCT03552692]); monoclonal antibodies targeting CD2 (e.g., siplizumab [NCT01445535]); CCR4 monoclonal antibodies (e.g., mogalizumab [NCT01611142]); FYN inhibitors; CD30 antibody drug conjugates (e.g., brentuximab [NCT01716806, NCT03496779]); ERB kinase inhibitors; VGEFR-2 inhibitors (e.g., apatinib [NCT03631862]); and PD-1 and PD-L1 inhibitors for immune modulation (e.g., pembrolizumab [NCT02535247], nivolumab [NCT03586999], durvalumab [NCT03161223], and avelumab [NCT03046953]).